Neurocrine Biosciences Reports Third Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. MU
4. ACN
5. IBM
6. META
7. SPY
8. NVDA
9. PRIM
10. PFE

Go back to Neurocrine Biosciences Reports Third Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance

Neurocrine Biosciences (NBIX) Tops Q3 EPS by 29c, Beats on Revenue; Offers FY24 Revenue Guidance

October 30, 2024 7:03 AM EDT

Neurocrine Biosciences (NASDAQ: NBIX) reported Q3 EPS of $1.81, $0.29 better than the analyst estimate of $1.52. Revenue for the quarter came in at $622.1 million versus the consensus estimate of $600.97 million.

GUIDANCE:

Neurocrine Biosciences sees FY2024 revenue of $2.3-2.32 billion, versus the consensus of... More